These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 14638885)

  • 1. Pyridostigmine in postpolio syndrome: no decline in fatigue and limited functional improvement.
    Horemans HL; Nollet F; Beelen A; Drost G; Stegeman DF; Zwarts MJ; Bussmann JB; de Visser M; Lankhorst GJ
    J Neurol Neurosurg Psychiatry; 2003 Dec; 74(12):1655-61. PubMed ID: 14638885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome.
    Trojan DA; Collet JP; Shapiro S; Jubelt B; Miller RG; Agre JC; Munsat TL; Hollander D; Tandan R; Granger C; Robinson A; Finch L; Ducruet T; Cashman NR
    Neurology; 1999 Oct; 53(6):1225-33. PubMed ID: 10522877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open trial of pyridostigmine in post-poliomyelitis syndrome.
    Trojan DA; Cashman NR
    Can J Neurol Sci; 1995 Aug; 22(3):223-7. PubMed ID: 8529175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticholinesterase-responsive neuromuscular junction transmission defects in post-poliomyelitis fatigue.
    Trojan DA; Gendron D; Cashman NR
    J Neurol Sci; 1993 Feb; 114(2):170-7. PubMed ID: 8383188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).
    Stam M; Wadman RI; Wijngaarde CA; Bartels B; Asselman FL; Otto LAM; Goedee HS; Habets LE; de Groot JF; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
    BMJ Open; 2018 Jul; 8(7):e019932. PubMed ID: 30061431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome.
    Nollet F; Horemans H; Beelen A
    Neurology; 2000 Sep; 55(6):899-901. PubMed ID: 10994028
    [No Abstract]   [Full Text] [Related]  

  • 7. Pyridostigmine reduces QTc interval during recovery from maximal exercise in ischemic heart disease.
    Castro RR; Serra SM; Porphirio G; Mendes FS; Oliveira LP; Nóbrega AC
    Int J Cardiol; 2006 Feb; 107(1):138-9. PubMed ID: 16337518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinergic stimulation with pyridostigmine protects against exercise induced myocardial ischaemia.
    Castro RR; Porphirio G; Serra SM; Nóbrega AC
    Heart; 2004 Oct; 90(10):1119-23. PubMed ID: 15367503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyridostigmine treatment trial in neurogenic orthostatic hypotension.
    Singer W; Sandroni P; Opfer-Gehrking TL; Suarez GA; Klein CM; Hines S; O'Brien PC; Slezak J; Low PA
    Arch Neurol; 2006 Apr; 63(4):513-8. PubMed ID: 16476804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment for postpolio syndrome.
    Koopman FS; Uegaki K; Gilhus NE; Beelen A; de Visser M; Nollet F
    Cochrane Database Syst Rev; 2011 Feb; (2):CD007818. PubMed ID: 21328301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure.
    Androne AS; Hryniewicz K; Goldsmith R; Arwady A; Katz SD
    Heart; 2003 Aug; 89(8):854-8. PubMed ID: 12860856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial.
    Schreglmann SR; Büchele F; Sommerauer M; Epprecht L; Kägi G; Hägele-Link S; Götze O; Zimmerli L; Waldvogel D; Baumann CR
    Eur J Neurol; 2017 Apr; 24(4):545-551. PubMed ID: 28224720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinergic stimulation improves autonomic and hemodynamic profile during dynamic exercise in patients with heart failure.
    Serra SM; Costa RV; Teixeira De Castro RR; Xavier SS; Nóbrega AC
    J Card Fail; 2009 Mar; 15(2):124-9. PubMed ID: 19254671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with L-citrulline in patients with post-polio syndrome: study protocol for a single-center, randomised, placebo-controlled, double-blind trial.
    Schmidt S; Gocheva V; Zumbrunn T; Rubino-Nacht D; Bonati U; Fischer D; Hafner P
    Trials; 2017 Mar; 18(1):116. PubMed ID: 28274276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticholinesterases in post-poliomyelitis syndrome.
    Trojan DA; Cashman NR
    Ann N Y Acad Sci; 1995 May; 753():285-95. PubMed ID: 7611637
    [No Abstract]   [Full Text] [Related]  

  • 16. Ocular effects of hyoscine in double dose transdermal administration and its reversal by low dose pyridostigmine.
    Alhalel A; Ziv I; Versano D; Ruach M; Alkalay M; Almog S; Izraeli S; Glovinsky J
    Aviat Space Environ Med; 1995 Nov; 66(11):1037-40. PubMed ID: 8588791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled trial of modafinil for the treatment of fatigue in postpolio patients.
    Chan KM; Strohschein FJ; Rydz D; Allidina A; Shuaib A; Westbury CF
    Muscle Nerve; 2006 Jan; 33(1):138-41. PubMed ID: 16175627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.
    Benatar M; Mcdermott MP; Sanders DB; Wolfe GI; Barohn RJ; Nowak RJ; Hehir M; Juel V; Katzberg H; Tawil R;
    Muscle Nerve; 2016 Mar; 53(3):363-9. PubMed ID: 26179124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of pyridostigmine administration on human neuromuscular functions--studies in healthy human subjects.
    Glikson M; Achiron A; Ram Z; Ayalon A; Karni A; Sarova-Pinchas I; Glovinski J; Revah M
    Fundam Appl Toxicol; 1991 Feb; 16(2):288-98. PubMed ID: 1647337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
    Tripathi M; Kaushik S; Dubey P
    J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.